COMMUNIQUÉS West-GlobeNewswire

Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity.
01/10/2019
Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. Amsterdam, The Netherlands – 1st October 2019 Esperite N.V. (the Group) confirmed on 22nd February 2019 the intentions [...]
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
01/10/2019
- Phase II results showed statistically significant pain relief through 24 weeks - Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 01, 2019 [...]
Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio
01/10/2019
- Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields - John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally closed on July 15 [...]
Third-party evaluation confirms safety profile of Philips Stellarex .035″ low-dose drug-coated balloon
01/10/2019
October 1, 2019 Primary safety analysis of Stellarex drug-coated balloon (DCB) three-year data, comprising the largest published, pooled set of randomized controlled trial (RCT) data for a single paclitaxel-based device [...]
Integrated Cannabis’ Ganja Gold takes Delivery of Fully Automated Proprietary Pre-Roll Manufacturing Machine
01/10/2019
VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“ Integrated Cannabis ” or the “ Company ”), a multi-state brand operator in California and [...]
iCAD Showcases ProFound AI™ Platform at European Society of Breast Imaging Annual Scientific Meeting in Budapest
01/10/2019
Company to exhibit ProFound AI for 2D and 3D Mammography in Europe NASHUA, N.H. and BUDAPEST, Hungary, Oct. 01, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative [...]
Eurobio Scientific joins the Enternext PEA PME 150 index
01/10/2019
Eurobio Scientific joins the Enternext PEA PME 150 index Paris, October 1st 2019 – 8:00 am Eurobio Scientific ( FR0013240934, ALERS), the leading French group in the field of in vitro medical diagnostics and life [...]
Eurobio Scientific entre dans l’indice Enternext PEA PME 150
01/10/2019
Eurobio Scientific entre dans l’indice Enternext PEA PME 150 Paris, le 1 er octobre 2019 – 8h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de [...]
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
01/10/2019
IPH5401 dose-escalation study in combination with durvalumab in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with [...]
INNATE PHARMA PRÉSENTE DES RESULTATS CLINIQUES PRELIMINAIRES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019
01/10/2019
Profil de sécurité gérable de la combinaison d’IPH5401 avec durvalumab dans l’étude en escalade de dose STELLAR-001 dans des tumeurs solides avancées Deux extensions de cohorte ont démarré : dans le cancer du poumon non [...]
IBA receives down payment for Proteus®PLUS contract in Shenzhen, China
01/10/2019
Seven proton therapy rooms already sold by IBA this year Louvain-la-Neuve, Belgium, 1 October, 2019 - IBA ( Ion Beam Applications SA ), the world’s leading provider of proton therapy solutions for the treatment of [...]
IBA reçoit l’acompte du contrat pour un Proteus®PLUS à Shenzhen en Chine
01/10/2019
IBA a déjà signé des contrats pour sept salles de protonthérapie cette année Louvain-La-Neuve, Belgique, 1 er octobre 2019 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de solutions de [...]
FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat
01/10/2019
SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for “On-Market Innovative Drug with Highest Clinical Value [...]
Chimerix Announces Exclusive Global License Agreement with SymBio Pharmaceuticals for Brincidofovir
01/10/2019
Includes All Human Indications Excluding Prevention and Treatment of Smallpox Chimerix to Receive up to $180 Million in Potential Clinical, Regulatory, and Commercial Milestones and is Eligible for Double Digit [...]
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
01/10/2019
LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/10/2019
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2019, that were [...]
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/09/2019
CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Genfit: H1 2019 Results and R&D Pipeline Progression
30/09/2019
GENFIT: H1 2019 RESULTS AND R&D PIPELINE PROGRESSION Cash position of €282 million (€207 million at December 31, 2018) USD $155 million gross proceeds from the IPO on the Nasdaq Global Select market Signature of a [...]
GENFIT présente ses résultats financiers et l’avancée de son portefeuille de programmes de R&D au premier semestre 2019
30/09/2019
GENFIT présente ses résultats financiers et l’avancée de son portefeuille de programmes de R&D au premier semestre 2019 Trésorerie de Cloture de 282 M€ (contre 207 M€ au 31 décembre 2018) Levée de fonds d’un montant [...]

Pages